Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has secured a licensing deal with Brazilian pharmaceutical company Blanver for BIO101 (20-Hydroxyecdysone) in Latin America.

The agreement is potentially worth up to EUR108m, including an upfront payment and further additional payments if certain objectives are achieved. Biophytis is also eligible to receive double-digit royalties on net sales of BIO101 (20-Hydroxyecdysone) generated in the collaboration territory, after obtaining future marketing authorisations.

Blanver will be responsible for the registration, marketing and commercialisation of BIO 101 (20-Hydroxyecdysone) in its indications -- including obesity, respiratory infections due to COVID-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) -- upon successful completion of Biophytis' clinical trials.